Summaries for patients. Underactive thyroid function after treatment with sunitinib for gastrointestinal cancer.
D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D004334:Drug Administration Schedule; D005260:Female; D046152:Gastrointestinal Stromal Tumors / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D007037:Hypothyroidism / Q000139:chemically induced*; D007211:Indoles / Q000008:administration & dosage / Q000009:adverse effects*; D011446:Prospective Studies; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011758:Pyrroles / Q000008:administration & dosage / Q000009:adverse effects*; D000077210:Sunitinib; D013966:Thyroiditis / Q000139:chemically induced; D013972:Thyrotropin / Q000097:blood
D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D013972:Thyrotropin; D011505:Protein-Tyrosine Kinases; D000077210:Sunitinib